shr2285
Small moleculeexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 31, 2019 (NCT03769831)
Timeline
Indications
Mechanism of action
- Coagulation factor XIINHIBITOR
F11 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05203705 | Phase 2 | Mar 8, 2022 | Hengrui Therapeutics, Inc. |
| NCT04945616 | Phase 1 | Jul 13, 2021 | Hengrui Therapeutics, Inc. |
| NCT04829305 | Phase 1 | May 20, 2021 | Atridia Pty Ltd. |
| NCT04472819 | Phase 1 | Aug 1, 2020 | Hengrui Therapeutics, Inc. |
| NCT04229433 | Phase 1 | Jan 31, 2020 | Hengrui Therapeutics, Inc. |
| NCT03769831 | Phase 1 | Jan 31, 2019 | Hengrui Therapeutics, Inc. |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2019 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1